German authorities approve cannabis for MS patient for first time

Posted : Mon, 03 Sep 2007 03:14:06 GMT
Author : DPA
Category : Health
News Alerts by Email ( click here )
Health News | Home
Berlin - Claudia H has become the first German to be allowed legal access to cannabis to treat the multiple sclerosis she has been suffering from for 14 years. Strict conditions apply to the permit, which came into effect in late August, and the treatment has to be conducted under the supervision of a doctor.

Despite the widespread evidence that cannabis can help MS patients, as well as cancer and HIV/AIDS sufferers, counter their pain and assist in curbing weight-loss, German doctors are not allowed to prescribe it.

A synthetic alternative is available in the form of Dronabinol, the active ingredient in cannabis, but the state health insurance will not pay the costs, and 60 capsules can cost up to 2,000 dollars.

Many patients resort to illegal sources for the drug, enduring the hassle of negotiating the drug-dealers' milieu and running the risk of brushes with the law.

Police and the courts in Germany tend to take a relaxed view on the possession of small quantities of cannabis, but practise varies from state to state.

Claudia H was one of those prepared to run the risks, even though at the age of 51, this ran counter to her nature.

"I tried out all the legal medications, but the side effects were unacceptable," the software technician told the Sueddeutsche newspaper.

She has been unable to walk for the past 10 years, and her condition began to deteriorate markedly five years ago.

"I couldn't sleep at night as a result of cramps, but if I took tablets, things were worse the next day," she said.

Dronabinol did not help either.

Then Claudia H saw an article in a magazine for MS patients. "I wanted to try it, and my doctor was in support," she said.

"I got hold of some cannabis, and now I make tea two or three times a week when the symptoms are bad."

She was immediately convinced. The paralysis was reduced, with the effects continuing into the next day.

Claudia H says she experiences no sensation of intoxication and no indication she has become dependent on the drug, but her medication remains technically illegal.

Now a central regulatory body called the Federal Opiate Authority has given Claudia H special permission to continue. Previous requests had been automatically turned down.

Other MS patients still have to apply individually for that permission, but the hope is that there has at last been a change in official thinking.

Copyright, respective author or news agency

Share/Save/Bookmark

Article : German authorities approve cannabis for MS patient for first time
Print this article
Email this article

Stay Updated
News gadget on your Google homepage
Subscribe to a news feed in Google Reader



Have your Say
Name
Email
Subject
Your Comment

Enter Verification code
 
  

 

 
Your Comments

cannabis for ms patients
By: holger roenitz , Mon, 03 Sep 2007 09:17:19 GMT

I have read your article with great interest and would like to add the following information for your readers.

Dronabinol sells in Germany at approx. 150 -170 € (200 - 230 US dollars) for 60 capsules (2.5 mg), you apparently quoted a price for MARINOL which is fully synthetic Dronabinol from the US.

If certain criterias are fulfilled the health insurance company will cover the costs although some try to use some loopholes in the law.

As far as the cannabis extract is concerned, patients unfortunately will have to pay it in full in all cases.

kind regards

Holger Roenitz




More Health News click here
Follow The Earth Times
Subscribe to RSS Follow Earth Times on TwitterNews by email
Share/Save/Bookmark

 
 



 
Subscribe to free Earthtimes
News Alerts by Email Click here
For RSS Feeds Click here
or Create your own RSS

Add to Google Toolbar
Breaking News
Press Releases


The Earth Times
News Category

© 2009 www.earthtimes.org, The Earth Times, All Rights Reserved | Privacy Policy
Earth Times accept no responsibility or liability either directly or indirectly for views or opinions expressed in articles or comments.